First, there was empagliflozin (Jardiance) showing a 14% RRR in 3-point MACE in diabetics in the EMPA-REG OUTCOMES trial. Now, another member of the SGLT-2 inhibitor class (canagliflozin; Invokana) was announced today to also achieve a 14% RRR in 3-point MACE in their CANVAS trial. Interestingly, there seems to be an increased risk of amputations with canagliflozin. Also, the 14% RRR achieved by Jardiance was almost exclusively due to reduced cardiovascular death with hardly any effect on heart attack or stroke. But Invokana's effects seem to be derived from all 3 components.

CANVAS: Canagliflozin Reduces CV Events, but at Cost of Amputations

J&J boasts improved cardio safety with SGLT2 franchise drug Invokana